Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
Leigh D Church1, Sinisa Savic2, Michael F McDermott21Department of Rheumatology, Division of Immunity, Infection and Inflammation, Institute for Biomedical Research, The University of Birmingham, Birmingham, UK; 2Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, Wellcome Tru...
Saved in:
Main Authors: | Leigh D Church, Sinisa Savic, Michael F McDermott |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2008
|
Subjects: | |
Online Access: | https://doaj.org/article/7c1d1dc2c87d46f3a90f0e2b1d4596ab |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
by: Justin Gillespie, et al.
Published: (2010) -
Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
by: Ori Toker, et al.
Published: (2010) -
Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
by: Pierre Quartier
Published: (2011) -
Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome
by: Kawai M, et al.
Published: (2013) -
Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin- associated periodic syndromes
by: Bachove I, et al.
Published: (2014)